Drug details

Reyvow (lasmiditan tablets)

type of Antimigraine Agents, Serotonin 5-HT1F Agonists

Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. Reyvow is not indicated for the preventive treatment of migraine.

The drug is often used to treat Migraine .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• fever,
• diarrhea
• sweating,
• agitation,
• shivering,
• vomiting, and
• hallucinations,
• twitching,
• fast heart rate,
• loss of coordination,
• muscle stiffness,

The following drugs are related to Reyvow, either as a replacement or used together:

• Midrin (acetaminophen, isometheptene and dichloralphenazone)
• Aimovig (erenumab-aooe injection, for subcutaneous use)
• Ajovy (fremanezumab-vfrm injection)
• Amerge (naratriptan)
• Qulipta (atogepant tablets)
• Fioricet with Codeine (butalbital acetaminophen caffeine capsules)
• Fioricet (butalbital and acetaminophen tablets)
• Relpax (eletriptan hydrobromide)
• Emgality (galcanezumab-gnlm injection)
• Vyepti (eptinezumab-jjmr injection for intravenous use)
• Imitrex (sumatriptan succinate)
• Maxalt (rizatriptan benzoate)
• Nurtec ODT (rimegepant orally disintegrating tablets, for sublingual or oral use)
• Treximet (sumatriptan and naproxen sodium tablets)
• Zecuity (sumatriptan iontophoretic transdermal system)